糖肽抗生素市场：按药物、按疾病适应症、按分销渠道、按地区 - 规模、份额、展望、机会分析，2022-2030 年

Glycopeptide Antibiotics Market, by Drug, by Disease Indication, by Distribution channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2030

出版日期: 2023年01月02日 | 出版商:

Coherent Market Insights | 英文 154 Pages | 商品交期: 2-3个工作天内

价格

简介目录

糖肽类抗生素是一类通过抑制肽聚醣合成来抑制细菌细胞壁形成的抗生素。糖肽类抗生素用于治疗腹泻、心内膜炎、艰难梭菌感染引起的肠炎、住院期间或使用呼吸机期间发生的肺炎以及严重的皮肤和皮肤结构感染。引起传染病的细菌大致分为两种类型：没有覆盖细胞壁的外膜的革兰氏阳性菌，以及具有覆盖细胞壁的额外膜的革兰氏阴性菌。革兰氏阴性菌对糖肽具有耐药性，因为它们有一层外膜可以防止糖肽进入细胞壁，儘管糖肽对革兰氏阳性菌的感染有效。

此外，一些糖肽可用于严重感染的静脉内给药和轻度感染的口服给药。糖肽类抗生素 (GPA) 通常用于治疗由金黄色葡萄球菌、肠球菌和艰难梭菌等多重耐药革兰氏阳性菌引起的危及生命的感染。首先从植物和土壤细菌中分离出一个抗生素家族，其结构包含糖基化环状或多环非核醣体肽。通过干扰肽聚醣的产生，这些抗生素会干扰易感生物（主要是革兰氏阳性球菌）的细胞壁组装。万古霉素、替考拉宁和雷莫拉宁是第一代糖肽类抗生素的例子。第二代半合成糖肽类抗生素包括奥利万星、达巴万星和特拉万星。

市场动态

糖肽类抗生素产品发布和批准的增加预计将在预测期内推动市场增长。例如，2019 年 6 月，生物製药公司 ANI Pharmaceuticals, Inc. 获得了美国 FDA 批准的盐酸万古霉素口服 USP 250mg/5ml 补充剂，用于治疗各种感染。

这项研究的主要特点

本报告详细分析了以 2021 年为基准年的预测期 (2022-2030) 的全球糖肽类抗生素市场、市场规模（百万美元）和復合年增长率 (CAGR%)。
解释了不同细分市场的潜在创收机会，并描述了针对该市场的有吸引力的投资建议矩阵。
它还提供有关市场促进因素、抑制因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争策略的重要见解。
根据以下参数介绍全球糖肽抗生素市场的主要参与者 - 公司亮点、产品组合、主要亮点、财务业绩和战略。
本研究涵盖的主要公司包括 ANI Pharmaceuticals, Inc.、Fresenius SE & Co. KGaA、Pfizer Inc.、Mylan N.V.、Novartis AG、Hikma Pharmaceuticals plc、Aurobindo Pharma、AbbVie Inc.、Melinta Therapeutics, Inc 、Cumberland Pharmaceuticals Inc.、Theravance Biopharma、Janssen Global Services, LLC、Bristol-Myers Squibb Company 和 GlaxoSmithKline plc。
这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。我猜。
《全球糖肽抗生素市场》报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
利益相关者可以通过用于分析全球糖肽抗生素市场的各种战略矩阵来促进决策制定。

北美
美国
加拿大
拉丁美洲
巴西
墨西哥
阿根廷
其他拉丁美洲地区
欧洲
德国
英国
法国
意大利
西班牙
俄罗斯
其他欧洲地区
亚太地区
中国
印度
日本
澳大利亚
韩国
东盟
其他亚太地区
中东
海湾合作委员会
以色列
其他中东地区
非洲
南非
中非
北非

第 9 章竞争格局

竞争快照
- Competitive Snapshot
  - ANI Pharmaceuticals, Inc.
- Fresenius SE & Co. KGaA
- Pfizer Inc
- Mylan N.V.
- Novartis AG
- Hikma Pharmaceuticals plc
- Aurobindo Pharma
- AbbVie Inc.
- Melinta Therapeutics, Inc
- Cumberland Pharmaceuticals Inc
- Theravance Biopharma
- Janssen Global Services, LLC
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc.
第 10 章
- 参考文献
- 调查方法

简介目录

Product Code: CMI5455

Glycopeptide antibiotics are the type of antibiotics that inhibit bacterial cell wall formation by inhibiting peptidoglycan synthesis. Glycopeptide antibiotics are used for the treatment of Clostridium difficile-associated diarrhea, endocarditis, enterocolitis Pneumonia acquired during a hospital stay or that develops while using a ventilator, and severe skin and skin structure infections. Gram-positive bacteria, which do not have an outer membrane covering their cell walls, and gram-negative bacteria, which have an additional membrane covering the cell walls, are the two main types of bacteria that cause infections. Gram-negative bacteria are resistant to glycopeptides because they have an outer membrane that prevents the entry of glycopeptides into their cell wall, although glycopeptides are effective against gram-positive bacterial infections.

Moreover, some glycoproteins are administered through the intravenous route in severe infection and oral treatment is used at the time of mild infection. Life-threatening infections brought on by multidrug-resistant Gram-positive organisms like Staphylococcus aureus, Enterococcus species, and Clostridium difficile are routinely treated using glycopeptide antibiotics (GPAs). One of a group of antibiotics has structures that contain either a glycosylated cyclic or polycyclic nonribosomal peptide that was first isolated from plant and soil bacteria. By preventing the manufacture of peptidoglycan, these antibiotics interfere with the cell wall construction of organisms that are sensitive (mostly Gram-positive cocci). Vancomycin, teicoplanin, and ramoplanin are examples of first-generation glycopeptide antibiotics. Oritavancin, dalbavancin, and telavancin are examples of second-generation semi-synthetic glycopeptide antibiotics.

Market Dynamics

Increasing product launch and approval of glycopeptide antibiotics are expected to drive the market growth over the forecast period. For instance, in June 2019, ANI Pharmaceuticals, Inc., a biopharmaceutical company received the U.S. FDA prior approval supplement for its Vancomycin Hydrochloride for Oral Solution USP, 250 mg/5 ml for the treatment of various infections.

Key features of the study:

This report provides an in-depth analysis of the global glycopeptide antibiotics market, market size (US$ Mn), and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global glycopeptide antibiotics market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include ANI Pharmaceuticals, Inc., Fresenius SE & Co. KGaA, Pfizer Inc., Mylan N.V., Novartis AG, Hikma Pharmaceuticals plc, Aurobindo Pharma, AbbVie Inc., Melinta Therapeutics, Inc, Cumberland Pharmaceuticals Inc., Theravance Biopharma, Janssen Global Services, LLC, Bristol-Myers Squibb Company, and GlaxoSmithKline plc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
The global glycopeptide antibiotics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global glycopeptide antibiotics market

Detailed Segmentation:

Global Glycopeptide Antibiotics Market, By Drug:
- Vancocin
- Orbactiv
- Dalvance
- Kimyrsa
- Others
Global Glycopeptide Antibiotics Market, By Disease Indication:
- Clostridium difficile-associated Diarrhea
- Endocarditis
- Skin Structure Infections
- Others
Global Glycopeptide Antibiotics Market, By Distribution Channel:
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
Global Glycopeptide Antibiotics Market, By Region:
- North America
  - By Country
- U.S.
- Canada
- Latin America
  - By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
  - By Country
- U.K.
- Germany
- France
- Spain
- Italy
- Russia
- Rest Of Europe
- Asia Pacific
  - By Country
- China
- India
- Japan
- ASEAN
- Australia
- South Korea
- Rest of Asia Pacific
- Middle East
  - By Country
- GCC
- Israel
- Rest of Middle East
- Africa
  - By Country/Region
- South Africa
- Central Africa
- North Africa
Company Profiles
- ANI Pharmaceuticals, Inc.*
  - Company Overview
  - Disease Indication Portfolio
  - Financial Overview
  - Key Highlights
  - Market Strategies
- Fresenius SE & Co. KGaA
- Pfizer Inc
- Mylan N.V.
- Novartis AG
- Hikma Pharmaceuticals plc
- Aurobindo Pharma
- AbbVie Inc.
- Melinta Therapeutics, Inc
- Cumberland Pharmaceuticals Inc
- Theravance Biopharma
- Janssen Global Services, LLC
- Bristol-Myers Squibb Company
- GlaxoSmithKline plc.

"*" marked represents similar segmentation in other categories in the respective section.

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug
- Market Snippet, By Disease Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Drivers
Restraints
Opportunities
Impact Analysis
Key Development Strategies
Mergers And Acquisition Scenario
Market Trends
Brand Analysis
Regulatory Scenario
PEST Analysis
Pricing Analysis

4. Global Glycopeptide Antibiotics Market - Impact of Coronavirus (Covid-19) Pandemic

COVID-19 Epidemiology
Impact on Manufacturing
Impact on Manufacturing

5. Global Glycopeptide Antibiotics Market, By Drug, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017-2030
- Segment Trends
Vancocin
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Orbactiv
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Dalvance
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Kimyrsa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

6. Global Glycopeptide Antibiotics Market, By Disease Indication, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017-2030
- Segment Trends
Clostridium difficile-associated Diarrhea
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Endocarditis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Skin Structure Infections
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

7. Global Glycopeptide Antibiotics Market, By Distribution Channel, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, 2017-2030
- Segment Trends
Hospital Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Retail Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)
Online Pharmacy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2017 - 2030, (US$ Mn)

8. Global Glycopeptide Antibiotics Market, By Region, 2017 - 2030, (US$ Mn)

Introduction
- Market Share Analysis, By Region, 2022 and 2030 (%)
- Y-o-Y Growth Analysis, For Regions, 2017-2030
North America
- Market Size and Forecast, By Drug, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
U.S.
Canada
Latin America
- Market Size and Forecast, By Drug, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
Brazil
Mexico
Argentina
Rest of Latin America
Europe
- Market Size and Forecast, By Drug, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
Asia Pacific
- Market Size and Forecast, By Drug, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
- Market Size and Forecast, By Drug, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Country, 2017 - 2030, (US$ Mn)
GCC
Israel
Rest of Middle East
Africa
- Market Size and Forecast, By Drug, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Disease Indication, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Distribution Channel, 2017 - 2030, (US$ Mn)
- Market Size and Forecast, By Region/Country, 2017 - 2030, (US$ Mn)
South Africa
Central Africa
North Africa

9. Competitive Landscape

Competitive Snapshot
- ANI Pharmaceuticals, Inc.*
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Fresenius SE & Co. KGaA
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Pfizer Inc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Mylan N.V.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Novartis AG
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Hikma Pharmaceuticals plc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Aurobindo Pharma
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
AbbVie Inc.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Melinta Therapeutics, Inc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Cumberland Pharmaceuticals Inc
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Theravance Biopharma
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Janssen Global Services, LLC
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
Bristol-Myers Squibb Company
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
GlaxoSmithKline plc.
- Company Overview
- Disease Indication Portfolio
- Financial Overview
- Key Highlights
- Market Strategies